Table 2.
Intraoperative data of CRS-HITOC.
| Study Population | Study Population |
|---|---|
| n = 350 | n (%) |
| Previous thoracic surgery (ipsilateral) | 270 (77.1) |
| Side of surgery | |
| left | 151 (43.1) |
| right | 199 (56.9) |
| Surgical cytoreduction | |
| P/D | 77 (22.0) |
| eP/D | 263 (75.1) |
| EPP | 10 (2.9) |
| Resection of | |
| diaphragm | 230 (65.7) |
| pericardium | 156 (44.6) |
| chest wall | 35 (10.0) |
| lung (wedge/atypical) | 133 (38.0) |
| lung (anatomical) | 24 (6.9) |
| Alloplastic reconstruction/replacement of | |
| diaphragm | 94 (26.9) |
| pericardium | 89 (25.4) |
| Intraoperative transfusion | 179 (51.1) |
| Intraoperative complication | 9 (2.6) |
| Weaning and extubation in the OR | 312 (89.1) |
| Resection status | |
| R0/R1 (macroscopic complete) | 300 (85.7) |
| R2 (macroscopic residual disease) | 50 (14.3) |
| Duration of HITOC | |
| (median, IQR) (min) | 60 (60–88) |
| Temperature perfusate (°C) | |
| minimum (median, IQR) (n = 313) | 41.5 (41.5–42.0) |
| maximum (median, IQR) (n = 323) | 42.0 (42.0–42.5) |
| Pump flow (mL/min) | |
| minimum (median, IQR) (n = 308) | 1000 (1000–1300) |
| maximum (median, IQR) (n = 307) | 1100 (1000–1500) |
| Perfusion volume (mL) | |
| (median, IQR) (n = 339) | 5000 (4500–5000) |
| Chemotherapeutic agents | |
| cisplatin | 212 (60.6) |
| cisplatin + doxorubicin | 138 (39.4) |
| Calculated dosages of both chemotherapeutic agents (mg/m2 BSA) | |
| cisplatin (n = 350) (median, IQR) | 108.8 (100–150) |
| doxorubicin (n = 138) (median, IQR) | 46.9 (35.7–52.9) |
| Cisplatin concentration (mg/m2 BSA) | |
| low-dose ≤ 125 | 234 (66.9) |
| high-dose > 125 | 116 (33.1) |
| Medicamentous cytoprotection | 178 (50.9) |
| Fluid balancing | 316 (90.3) |
| Complications during HITOC | 6 (1.7) |
BSA = body surface area; IQR = interquartile range; P/D = pleurectomy/decortication; eP/D = extended pleurectomy/decortication; EPP = extrapleural pneumonectomy, OR = operating room.